Edgewise Therapeutics (EWTX) said Thursday that the US Food and Drug Administration's warning to Han Phan at Rare Disease Research is "unrelated" to any of the company's clinical trials or data.
The warning letter issued on Nov. 27 following a site inspection was related to Phan's work with another company, according to Edgewise.
Edgewise said it has audited Phan's site multiple times and believes the data related to its clinical trials complies with the FDA's requirements.
Shares of the company were down 1.6% in recent trading.
Price: 31.56, Change: -0.50, Percent Change: -1.56
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。